The Massachusetts-based biotech is awaiting a decision in the U.S., where the FDA recently extended its review after agency advisers narrowly voted against the treatment.

Agency scientists found the shots to be similarly effective in kids as in older teenagers and raised no major safety red flags, documents published ahead of a meeting of agency advisers this week show.

The pandemic motivated sponsors to reimagine decentralized trials and realize the benefits these models deliver.

Arising from the circumstances in which people grow, live, work and age, and the systems put in place to deal with illness, these health inequities are avoidable. 

Positive data from 75 patients with either sickle cell disease or beta thalassemia keep the companies’ therapy on track to become the first CRISPR-based treatment submitted to drug regulators, possibly by the end of the year.

By a 13-0 vote, the panel agreed the benefits of Bluebird’s beta thalassemia treatment outweigh its risks, one day after reaching a similar conclusion for another of the company’s drugs.

The British drugmaker now plans to seek approval of what could be the first preventive shot for the common lung infection. However, Pfizer, Johnson & Johnson and Moderna are close behind. 

Three of the six lymphoma patients who received Caribou’s gene editing treatment have relapsed in the latest sign that so-called allogeneic drugs could have trouble matching their CAR-T counterparts. 

The European venture firm’s latest fund will open up a new source of investment at a time companies are struggling to go public or hold their value.